ABSTRACT Alzheimer's disease (AD) is a neurodegenerative disorder. Irreversible pathological alterations are already present when clinical symptoms emerge. Therefore, early diagnosis and intervention are crucial for improving patient outcomes and reducing the social and healthcare burden. With its advantages of minimal invasiveness, convenience, affordability, and high accessibility, blood‐based testing has overcome the limitations of conventional methods, becoming a major focus of research in early AD diagnosis in recent years. Based on the key domestic and international research findings in recent years, this paper systematically reviews the types, mechanisms of action, and relevant detection technologies of blood‐based biomarkers for AD.
Shuangshuang Li, Lin Huang, Qihao Guo. Blood‐Based Biomarkers in Alzheimer's Disease: Advances in Detection Technologies and Clinical Applications. // Aging Medicine. – 2026. – DOI: 10.1002/agm2.70112. – URL: https://onlinelibrary.wiley.com/doi/10.1002/agm2.70112?af=R
Shuangshuang Li, Lin Huang, & Qihao Guo (2026). Blood‐Based Biomarkers in Alzheimer's Disease: Advances in Detection Technologies and Clinical Applications. Aging Medicine. https://doi.org/10.1002/agm2.70112
Shuangshuang Li, et al. “Blood‐Based Biomarkers in Alzheimer's Disease: Advances in Detection Technologies and Clinical Applications.” Aging Medicine, 2026. doi:10.1002/agm2.70112.
@article{Li2026,
title = {Blood‐Based Biomarkers in Alzheimer's Disease: Advances in Detection Technologies and Clinical Applications},
author = {Li, Shuangshuang and Huang, Lin and Guo, Qihao},
journal = {Aging Medicine},
year = {2026},
doi = {10.1002/agm2.70112},
url = {https://onlinelibrary.wiley.com/doi/10.1002/agm2.70112?af=R}
}
npj Aging, Published online: 19 November 2026; doi:10.1038/s41514-026-00570-8 Nicotinamide deficiency in the aqueous humor of patients with glaucoma revealed by LC-MS/MS
npj Aging, Published online: 19 November 2026; doi:10.1038/s41514-026-00566-4 Organ-specific proteomic aging in Chinese adults: 20-year clinical outcomes and metabolomic underpinnings